However, G1202R was shown to reduce the sensitivity of tumor cells to brigatinib and loratinib, and tumor cells harboring double mutations (D1203N+E1210K and F1174C+D1203N) had lower sensitivity to loratinib, whereas none of the second-generation ALK TKIs were effective (54). The gene discussed is ALK; the disease is neoplasm.